A preclinical study showed that PI3K inhibitors can prevent the development of acquired endocrine resistance and induce apoptosis in ER+ breast cancer cells with PIK3CA mutations under estradiol deprivation82. The gene discussed is PIK3CA; the disease is breast cancer.